首页 | 本学科首页   官方微博 | 高级检索  
检索        

碳青霉烯类抗生素的发展与展望
引用本文:董耘婷,张永信.碳青霉烯类抗生素的发展与展望[J].上海医药,2011,32(7):316-319.
作者姓名:董耘婷  张永信
作者单位:1. 复旦大学附属公共卫生临床中心,上海,201508
2. 复旦大学附属华山医院,上海,200040
摘    要:碳青霉烯类抗生素为一组具有特定分子结构的β-内酰胺类抗生素,对β-内酰胺酶相当稳定,杀菌活性优于头孢菌素类抗生素,是治疗产超广谱β-内酰胺酶和头孢菌素酶等多重耐药菌所致院内严重感染的首选药物。本文简述碳青霉烯类抗生素的发展史,着重介绍亚胺培南、美罗培南、比阿培南、帕尼培南、多利培南和泰吡培南酯等药物的特点及临床地位。

关 键 词:碳青霉烯类抗生素  亚胺培南  美罗培南  比阿培南  帕尼培南  厄他培南  多利培南  泰吡培南酯

The current development and prospects of carbapenems
DONG Yun-ting,ZHANG Yong-xin.The current development and prospects of carbapenems[J].Shanghai Medical & Pharmaceutical Journal,2011,32(7):316-319.
Authors:DONG Yun-ting  ZHANG Yong-xin
Institution:DONG Yun-ting 1*,ZHANG Yong-xin 2** (1.Shanghai Public Health Clinical Center affiliated to Fudan University,Shanghai,201508,2.Huashan Hospital affiliated to Fudan University,200040)
Abstract:Carbapenems with a special β-lactam structure are stable to most clinically findingβ-lactamases. They have potent bactericidal activity against a wide range of Gram-positive and Gram-negative aerobic bacteria,which is superior to that of cephalosporins in safety,efficacy and tolerability.Carbapenems have been used to treat the bacterial infections caused by extended-spectrum-β-lactamase-producing Escherichia coli and Klebsiella species and multidrug-resistant nosocomial infections.The development history and unique advantages of carbapenems are briefly introduced in this review with focus on the specificity and clinical position of those products including imipenem,meropenem,biapenem,panipenem,doripenem and tibipenem pivoxil.
Keywords:carbapanems  imipenem  meropenem  biapenem  panipenem  ertapenem  doripenem  tebipenem pivoxil  
本文献已被 CNKI 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号